Alzheimer’s Disease

The team prompted the chatbot to review the biomedical research literature and suggest 20 drugs for Alzheimer’s disease, ranking them for potential effectiveness. With a second prompt they asked for confirmation of the initial 20 suggestions. They repeated both prompts 10 times. Read More

Phase I clinical trial of a drug was successfully completed at the Warren Center for Neuroscience Drug Discovery, with promise to treat Alzheimer’s and other neurodegenerative diseases. The compound, named VU319, is the first Vanderbilt end-to-end drug discovery effort related to memory loss, starting from the earliest basic science research through human clinical trials. Read More